CD86 and neoplasm: Similarly, silk HGs administered s.c. to the tissue i.l. to the tumor facilitated improved accumulation of the immunotherapeutics (herein, neoantigens, CpG, and STING agonist 2, 3-cyclic-GMP-AMP (cGAMP)) in dLNs, leading to significant suppression of tumor growth with the expansion of activated DCs (CD86+CD80+ CD45+CD11c+) in dLNs and activated CD8+ T cells (41BB+ CD45+CD3+CD8+) in tumors [172].